| Abstract [eng] |
The increasing incidence of oncological diseases in Lithuania and the active treatment of these diseases are leading to an increase in cardiovascular complications. With the enhancement of anti-cancer treatment, it has been observed that it often becomes a cause of serious cardiovascular complications, which worsens the survival of cancer patients. Cardiovascular disease is a common cause of death in cancer survivors. The dissertation consists of three parts. In the clinical study "Development of a Cardio-Oncology Service in Lithuania: prediction, prevention, monitoring and treatment of cancer treatment-induced cardiotoxicity", we found that cancer patients are usually referred to a cardiologist for cardiotoxic lesion risk assessment after the beginning of cardiotoxic cancer treatment due to treatment complications, rather than before cancer treatment. Patients at low and high risk of cardiotoxic lesions are more likely to be referred to a cardiologist and would benefit from this consultation to reduce their risk of cardiac damage, optimise treatment of existing heart disease and correct cardiovascular risk factors. In the second study, "The prevalence of iron deficiency and anemia and their impact on survival in patients at a cardio-oncology clinic", we found that iron deficiency is common in cardio-oncology patients and affects their survival. In the third study, "Ivabradine to prevent anthracycline-induced cardiotoxicity: a prospective randomized open-label clinical trial", we showed that ivabradine can protect anthracycline-treated patients with a heart rate > 75 bpm from early mild cardiotoxicity. |
